Stocksigma LogoStocksigma Logo

Rekvina Laboratories Board Approvals, Preferential Issue Statement, and Key Executive Appointment

Rekvina Laboratories approved its standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26, accompanied by

Rekvina Laboratories Board Approvals, Preferential Issue Statement, and Key Executive Appointment

Rekvina Laboratories Ltd · Others (Uncategorized) · 13 Nov 2026, 11:57 pm

Rekvina Laboratories Board Approvals, Preferential Issue Statement, and Key Executive Appointment Rekvina Laboratories approved its standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26, accompanied by limited review reports. The company reported zero deviation in the utilization of ₹46 lakh raised via a preferential issue on 12th Aug'26, allocated toward working capital (₹40 lakh) and general corporate purposes (₹6 lakh), with nil funds deployed as of 30th Sep'26. Additionally, the Board appointed Ms. Bhagyshree Manojbhai Kandoi as Company Secretary and Compliance Officer, effective 16th Nov'26.

Original exchange filing (PDF)

More announcements from Rekvina Laboratories Ltd

All Rekvina Laboratories Ltd announcements